AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models (Q33770856)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

ChEBI release 2020-05-28

inflammatory breast cancer

1 reference

based on heuristic

inferred from title

Massimo Cristofanilli

7

object named as

Massimo Cristofanilli

1 reference

Europe PubMed Central

29 July 2017

author name string

Zhaomei Mu

1

1 reference

Europe PubMed Central

29 July 2017

Teresa Klinowska

2

1 reference

Europe PubMed Central

29 July 2017

Xiaoshen Dong

3

1 reference

Europe PubMed Central

29 July 2017

Emily Foster

4

1 reference

Europe PubMed Central

29 July 2017

Chris Womack

5

1 reference

Europe PubMed Central

29 July 2017

Sandra V Fernandez

6

1 reference

Europe PubMed Central

29 July 2017

publication date

30 May 2014

1 reference

Europe PubMed Central

29 July 2017

Journal of Experimental & Clinical Cancer Research

1 reference

Europe PubMed Central

29 July 2017

33

1 reference

Europe PubMed Central

29 July 2017

47

1 reference

Europe PubMed Central

29 July 2017

https://scigraph.springernature.com/pub.10.1186/1756-9966-33-47

0 references

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer (IBC): clues for targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Role of epidermal growth factor receptor in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer: what progress have we made?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer: the disease, the biology, the treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Molecular targets for treatment of inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Approach to inflammatory breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Prognostic markers in triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Inflammatory breast cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061513

4 July 2018

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-33-47

21 January 2018

Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-33-47

21 January 2018

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-33-47

21 January 2018

Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends for Inflammatory Breast Cancer: Is Survival Improving?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/24886365

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-9966-33-47

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33770856&oldid=1973354930"